Key result
Each standard deviation decrease in baseline mitochondrial DNA copy number was associated with a 34% higher risk of incident heart failure in middle-aged women.
Why the study?
Heart failure risk factors seem to differ between sexes and significant gaps in sex-specific knowledge exist, prompting investigation into baseline mitochondrial DNA copy number in women.
Does lower baseline mitochondrial DNA copy number increase the risk of incident heart failure and mortality in middle-aged women?
Cohort (n=2,508)
Does lower baseline mitochondrial DNA copy number increase the risk of incident heart failure and mortality in middle-aged women?
Hazard Ratio: 1.34 (95% CI 1.11–1.63)
p-value: p=0.003
Low baseline mitochondrial DNA copy number is an independent, easily quantifiable molecular risk factor for incident heart failure and overall mortality in middle-aged women.
Lower mtDNA-CN was associated with higher HF incidence in middle-aged women; leaves open its value as biomarker or causal target.
Heart failure (HF) is a leading cause of death in both men and women. However, risk factors seem to differ for men and women and significant gaps in sex-specific knowledge exist. Mitochondria are critical for cardiomyocytes and in this study, we investigated the role of baseline mitochondrial DNA copy number (mtDNA-CN) in HF incidence in middle-aged women and its possible role in the association between myocardial infarction (MI) and HF. Finally, we also investigated whether baseline mtDNA-CN was associated with overall and HF mortality. Baseline levels of mtDNA-CN were quantified by droplet digital PCR in a population-based follow-up study of middle-aged (50–59 years) Swedish women ( n = 2,508). The median follow-up period was 17 years. Levels of mtDNA-CN were associated with age, BMI, alcohol, smoking, education, physical activity and lipid biomarkers. Multivariable Cox regression analysis adjusted for potential confounders showed that each standard deviation decrease of baseline mtDNA-CN was associated with higher incidence of HF (HR = 1.34; 95% CI=1.11–1.63). Similar results were obtained when mtDNA-CN levels were categorized into quartiles with lowest vs. highest quartile showing the highest risk of HF incidence (HR = 2.04 95% CI=1.14; 3.63). We could not detect any role of mtDNA-CN in the association between MI and HF incidence. Lower baseline mtDNA-CN levels were associated with both overall (HR = 1.27; 95% CI=1.10–1.46) and HF mortality (HR = 1.93; 95% CI=1.04–3.60); however, in multivariable analysis adjusted for potential confounders, the higher risks of HF mortality were no longer significant (HR=1.57; 95% CI=0.85–2.90). In conclusion, low baseline mtDNA-CN is an easily quantifiable molecular risk factor for HF incidence and may be a risk factor for overall and HF-related mortality.
No takes yet. Share an insight, caveat, or question.
Sundquist et al. (2022) conducted a cohort in Heart failure (n=2,508). Baseline mitochondrial DNA copy number (mtDNA-CN) vs. Higher mtDNA-CN (per standard deviation increase) was evaluated on Incident heart failure (HR 1.34, 95% CI 1.11-1.63, p=0.003). Each standard deviation decrease in baseline mitochondrial DNA copy number was associated with a 34% higher risk of incident heart failure in middle-aged women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: